Use, method and composition for inhibiting and / or slowing down the decomposition of hyaluronic acid or a salt thereof, and / or for maintaining the action of hyaluronic acid or a salt thereof

Abstract

This application provides the use of a collagen-based substance, a combination of a collagen-based substance and chondroitin sulfate, a composition containing a collagen-based substance, or a composition containing a collagen-based substance and chondroitin sulfate in inhibiting and / or slowing down the degradation of hyaluronic acid or its salts, and / or maintaining the effects of hyaluronic acid or its salts. This application also provides a composition containing hyaluronic acid or its salts, comprising hyaluronic acid or its salts, a collagen-based substance, and / or chondroitin sulfate. This application inhibits and / or slows down the degradation of hyaluronic acid or its salts, maintains the effects of hyaluronic acid or its salts, avoids the human safety risks associated with adding enzyme preparations to the formulation, and safely and effectively prolongs the effects of hyaluronic acid or its salts.

Description

Technical Field

[0001] This application relates to the field of cosmetic technology, and in particular to the use, method and composition of inhibiting and / or slowing down the decomposition of hyaluronic acid or its salts, and / or maintaining the effect of hyaluronic acid or its salts. Background Technology

[0002] Hyaluronic acid (HA) is widely used in skincare formulations as a natural moisturizing factor. However, when applied to the skin, it is broken down into oligosaccharides or monosaccharides by HA-degrading enzymes, thus losing its intended skincare benefits. Existing technologies have involved adding enzyme inhibitors to formulations to slow down HA breakdown, but this poses safety risks to humans and may lead to HA metabolic disorders. Summary of the Invention

[0003] To solve the above problems, the inventors of this application discovered that a collagen substance of a certain molecular weight, or a combination of a collagen substance of a certain molecular weight and chondroitin sulfate, can inhibit and / or slow down the decomposition of hyaluronic acid or its salts, and maintain the function of hyaluronic acid or its salts, thereby completing the present invention.

[0004] The technical solution of this application is as follows:

[0005] 1. Use of collagen-based substances, combinations of collagen-based substances and chondroitin sulfate, compositions containing collagen-based substances, or compositions containing collagen-based substances and chondroitin sulfate in inhibiting and / or slowing down the decomposition of hyaluronic acid or its salts, and / or maintaining the action of hyaluronic acid or its salts.

[0006] 2. The use according to item 1, wherein the molecular weight of the collagen-like substance is 1w-9w Da.

[0007] 3. According to the use described in item 1, wherein,

[0008] When the collagen-like substance is used to achieve the stated purpose, the mass ratio of the collagen-like substance to the hyaluronic acid or its salt is (0.5–200):1; or,

[0009] When the combination of the collagen-like substance and chondroitin sulfate is used to achieve the above purpose, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagen-like substance to the mass ratio of the hyaluronic acid or its salt is (0.5-200):1. Preferably, the mass ratio of the chondroitin sulfate and the collagen-like substance is greater than or equal to 1:1, and more preferably (1-29):1.

[0010] 4. The use according to item 1, wherein the hyaluronic acid or its salt used to achieve the use has a molecular weight of 180 w Da or less.

[0011] 5. A composition containing hyaluronic acid or a salt thereof, wherein the composition comprises hyaluronic acid or a salt thereof and a collagen-like substance, the collagen-like substance having a molecular weight of 1w-9w Da;

[0012] Preferably, the mass ratio of the collagen-like substance to the hyaluronic acid or its salt is (0.5-200):1.

[0013] 6. A composition containing hyaluronic acid or a salt thereof, wherein the composition comprises hyaluronic acid or a salt thereof, a collagen-like substance, and chondroitin sulfate;

[0014] Preferably, the molecular weight of the collagen-like substance is 1w-9w Da;

[0015] Preferably, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagenous substance to the mass ratio of the hyaluronic acid or its salt is (0.5-200):1;

[0016] Preferably, the mass ratio of chondroitin sulfate to collagen is greater than or equal to 1:1, more preferably (1-29):1.

[0017] 7. The composition according to item 5 or 6, wherein,

[0018] The hyaluronic acid or its salt has a molecular weight of less than 180 w Da.

[0019] 8. Use of the composition of any one of items 5-7 in cosmetics.

[0020] 9. Use of the composition of any one of items 5-7 in inhibiting and / or slowing down the decomposition of hyaluronic acid or its salts, and / or maintaining the action of hyaluronic acid or its salts.

[0021] 10. A method for inhibiting and / or slowing down the decomposition of hyaluronic acid or its salts, and / or maintaining the effects of hyaluronic acid or its salts, the method comprising the following steps:

[0022] Collagenous substances, or a combination of collagenous substances and chondroitin sulfate, are added to an aqueous medium containing hyaluronic acid or its salts.

[0023] 11. According to the method of item 10, the molecular weight of the collagen-like substance is 1w-9w Da;

[0024] Preferably, the mass ratio of the collagen-like substance to the hyaluronic acid or its salt, or the mass ratio of the combination of the collagen-like substance and chondroitin sulfate to the hyaluronic acid or its salt, is (0.5-200):1;

[0025] Preferably, the mass ratio of chondroitin sulfate to collagen is greater than or equal to 1:1, more preferably (1-29):1;

[0026] Preferably, the molecular weight of the hyaluronic acid or its salt is less than 180 w Da.

[0027] Compared with the prior art, the beneficial effects of this application are: inhibiting and / or slowing down the degradation of hyaluronic acid or its salts, maintaining the function of hyaluronic acid or its salts, avoiding the human safety risks caused by adding enzyme preparations to the formula, and safely and effectively prolonging the function of hyaluronic acid or its salts. Detailed Implementation

[0028] The present application is further illustrated below with reference to embodiments. It should be understood that the embodiments are only used to further illustrate and explain the present application and are not intended to limit the present application.

[0029] Unless otherwise defined, technical and scientific terms used in this specification have the same meaning as commonly understood by one of ordinary skill in the art. While similar or identical methods and materials may be applied in experimental or practical applications, materials and methods are described herein. In case of conflict, the definitions included herein shall prevail. Furthermore, materials, methods, and examples are for illustrative purposes only and are not intended to be limiting. The present application is further described below with reference to specific embodiments, but is not intended to limit the scope of the application.

[0030] This application provides the use of collagen-based substances, combinations of collagen-based substances and chondroitin sulfate, compositions containing collagen-based substances, or compositions containing collagen-based substances and chondroitin sulfate in inhibiting and / or slowing down the decomposition of hyaluronic acid or its salts, and / or maintaining the effects of hyaluronic acid or its salts; that is, this application provides the use of collagen-based substances in inhibiting and / or slowing down the decomposition of hyaluronic acid or its salts, or the use of combinations of collagen-based substances and chondroitin sulfate in inhibiting and / or slowing down the decomposition of hyaluronic acid or its salts, or the use of collagen-based substances in maintaining the effects of hyaluronic acid or its salts, or the use of combinations of collagen-based substances and chondroitin sulfate in maintaining the effects of hyaluronic acid or its salts.

[0031] In some embodiments of this application, the type of collagen-like substance is not limited in any way, as long as the molecular weight is between 1w and 9wDa. For example, it can be collagen obtained by hydrolysis or collagen that has not been hydrolyzed.

[0032] In some embodiments of this application, the molecular weight of the collagen-like substance is 1w-9wDa; preferably, the molecular weight of the collagen-like substance is 3w-7wDa; for example, the molecular weight of the collagen-like substance can be any range of 1wDa, 2wDa, 3wDa, 4wDa, 5wDa, 6wDa, 7wDa, 8wDa, 9wDa or between.

[0033] In some embodiments of this application, the collagen-like substance includes hydrolyzed collagen.

[0034] The hydrolyzed collagen, i.e., the hydrolyzed product of collagen, is the product obtained by hydrolyzing collagen. This application does not impose any restrictions on the hydrolysis method; for example, alkaline, acidic, saline-alkali, and / or enzymatic methods can be used. This application also does not impose any restrictions on the source of the collagen; for example, it can be extracted from animal skin, tendons, or bone tissue.

[0035] In some embodiments of this application, the hydrolyzed collagen includes gelatin.

[0036] In some embodiments of this application, the collagen-like substance includes soluble collagen.

[0037] The soluble collagen is a soluble collagen derived from tissues. Depending on the soluble solvent used, it can be broadly classified into neutral salt soluble collagen and acidic soluble collagen.

[0038] In some embodiments of this application, when the collagen-like substance is used to achieve the stated purpose, the mass ratio of the collagen-like substance to the hyaluronic acid or its salt is (0.5–200):1; for example, it can be 0.5:1, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, 25:1, 30:1, 3... 5:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 100:1, 110:1, 120:1, 130:1, 140:1, 150:1, 160:1, 170:1, 180:1, 190:1, 200:1, or any range between them.

[0039] In some embodiments of this application, when the combination of the collagen-like substance and chondroitin sulfate is used to achieve the aforementioned purpose, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagen-like substance to the mass ratio of the hyaluronic acid or its salt is (0.5–200):1; for example, it can be 0.5:1, 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 15:1, 20:1, etc. 25:1, 30:1, 35:1, 40:1, 45:1, 50:1, 55:1, 60:1, 65:1, 70:1, 75:1, 80:1, 85:1, 90:1, 95:1, 100:1, 110:1, 120:1, 130:1, 140:1, 150:1, 160:1, 170:1, 180:1, 190:1, 200:1, or any range thereof.

[0040] In some embodiments of this application, the salt of hyaluronic acid is a sodium salt, potassium salt, magnesium salt, calcium salt, zinc salt, bismuth salt of hyaluronic acid, or a combination of two or more of them.

[0041] In some embodiments of this application, the molecular weight of the hyaluronic acid or its salt is less than 180 w Da, for example, it can be 180 w Da, 170 w Da, 160 w Da, 150 w Da, 140 w Da, 130 w Da, 120 w Da, 110 w Da, 100 w Da, 90 w Da, 80 w Da, 70 w Da, 60 w Da, 50 w Da, 40 w Da, 30 w Da, 20 w Da, 10 w Da, 9 w Da, 8 w Da, 7 w Da, 6 w Da, 5 w Da, 4 w Da, 3 w Da, 2 w Da, 1 w Da, 9000 Da, 8000 Da, 7000 Da, 6000 Da, 5000 Da, 4000 Da, 3000 Da, 2000 Da, 1000 Da, less than 1000 Da, or any range between these values.

[0042] In some embodiments of this application, when the combination of the collagen-like substance and chondroitin sulfate is used to achieve the aforementioned purpose, the mass ratio of the chondroitin sulfate to the collagen-like substance is greater than or equal to 1:1, preferably (1 to 29):1; the mass ratio of the chondroitin sulfate to the collagen-like substance can be 1:1, 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, 20:1, 21:1, 22:1, 23:1, 24:1, 25:1, 26:1, 27:1, 28:1, 29:1 or greater than 29:1, or any range between them.

[0043] In some embodiments of this application, when the collagen-like substance is used to achieve the stated purpose, the mass ratio of the collagen-like substance to the hyaluronic acid or its salt is (0.5 to 200):1, wherein the molecular weight of the collagen-like substance is 1w-9w Da, and the molecular weight of the hyaluronic acid or its salt is less than 180w Da.

[0044] In some embodiments of this application, when the collagen-like substance is used to achieve the stated purpose, the mass ratio of the collagen-like substance to the hyaluronic acid or its salt is (0.5 to 200):1, wherein the molecular weight of the collagen-like substance is 3w-7w Da, and the molecular weight of the hyaluronic acid or its salt is less than 180w Da.

[0045] In some embodiments of this application, when the combination of the collagen-like substance and chondroitin sulfate is used to achieve the intended use, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagen-like substance to the mass of the hyaluronic acid or its salt is (0.5-200):1, the mass ratio of the chondroitin sulfate and the collagen-like substance is greater than or equal to 1:1, and the molecular weight of the collagen-like substance is 1w-9w Da.

[0046] In some embodiments of this application, when the combination of the collagen-like substance and chondroitin sulfate is used to achieve the stated purpose, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagen-like substance to the mass ratio of the hyaluronic acid or its salt is (0.5-200):1, the mass ratio of the chondroitin sulfate and the collagen-like substance is greater than or equal to 1:1, wherein the molecular weight of the collagen-like substance is 1w-9w Da, and the molecular weight of the hyaluronic acid or its salt is less than 180w Da.

[0047] In some embodiments of this application, when the combination of the collagen-like substance and chondroitin sulfate is used to achieve the stated purpose, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagen-like substance to the mass ratio of the hyaluronic acid or its salt is (0.5-200):1, the mass ratio of the chondroitin sulfate and the collagen-like substance is greater than or equal to 1:1, wherein the molecular weight of the collagen-like substance is 3w-7w Da, and the molecular weight of the hyaluronic acid or its salt is less than 180w Da.

[0048] In some embodiments of this application, when the combination of the collagen-like substance and chondroitin sulfate is used to achieve the intended use, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagen-like substance to the mass of the hyaluronic acid or its salt is (0.5-200):1, the mass ratio of the chondroitin sulfate to the collagen-like substance is (1-29):1, and the molecular weight of the collagen-like substance is 1w-9w Da.

[0049] In some embodiments of this application, when the combination of the collagen-like substance and chondroitin sulfate is used to achieve the intended use, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagen-like substance to the mass ratio of the hyaluronic acid or its salt is (0.5-200):1, the mass ratio of the chondroitin sulfate to the collagen-like substance is (1-29):1, wherein the molecular weight of the collagen-like substance is 1w-9w Da, and the molecular weight of the hyaluronic acid or its salt capable of achieving the intended use is 180w Da or less.

[0050] In some embodiments of this application, when the combination of the collagen-like substance and chondroitin sulfate is used to achieve the stated purpose, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagen-like substance to the mass ratio of the hyaluronic acid or its salt is (0.5-200):1, the mass ratio of the chondroitin sulfate to the collagen-like substance is (1-29):1, wherein the molecular weight of the collagen-like substance is 3w-7w Da, and the molecular weight of the hyaluronic acid or its salt is less than 180w Da.

[0051] This application provides a composition containing hyaluronic acid or a salt thereof, wherein the composition comprises the aforementioned hyaluronic acid or a salt thereof and the aforementioned collagen-like substance; or, the composition comprises a combination of the aforementioned hyaluronic acid or a salt thereof, the aforementioned collagen-like substance and the aforementioned chondroitin sulfate.

[0052] In some embodiments of this application, when the composition comprises the above-mentioned hyaluronic acid or its salt and the above-mentioned collagen-like substance, the mass ratio of the collagen-like substance to the hyaluronic acid or its salt is (0.5 to 200):1, wherein the molecular weight of the collagen-like substance is 1w-9w Da, and the molecular weight of the hyaluronic acid or its salt is less than 180w Da.

[0053] In some embodiments of this application, when the composition includes the above-mentioned hyaluronic acid or its salt and the above-mentioned collagen-like substance, the mass ratio of the collagen-like substance to the hyaluronic acid or its salt is (0.5 to 200):1, wherein the molecular weight of the collagen-like substance is 3w-7w Da, and the molecular weight of the hyaluronic acid or its salt is less than 180w Da.

[0054] In some embodiments of this application, when the composition comprises a combination of the above-mentioned hyaluronic acid or its salt, the above-mentioned collagenous substance and the above-mentioned chondroitin sulfate, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagenous substance to the mass of the hyaluronic acid or its salt is (0.5 to 200):1, the mass ratio of the chondroitin sulfate and the collagenous substance is greater than or equal to 1:1, wherein the molecular weight of the collagenous substance is 1w-9w Da, and the molecular weight of the hyaluronic acid or its salt is less than 180w Da.

[0055] In some embodiments of this application, when the composition comprises a combination of the above-mentioned hyaluronic acid or its salt, the above-mentioned collagenous substance and the above-mentioned chondroitin sulfate, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagenous substance to the mass of the hyaluronic acid or its salt is (0.5 to 200):1, the mass ratio of the chondroitin sulfate and the collagenous substance is greater than or equal to 1:1, wherein the molecular weight of the collagenous substance is 3w-7w Da, and the molecular weight of the hyaluronic acid or its salt is less than 180w Da.

[0056] In some embodiments of this application, when the composition comprises a combination of the above-mentioned hyaluronic acid or its salt, the above-mentioned collagenous substance and the above-mentioned chondroitin sulfate, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagenous substance to the mass of the hyaluronic acid or its salt is (0.5-200):1, the mass ratio of the chondroitin sulfate to the collagenous substance is (1-29):1, and the molecular weight of the collagenous substance is 1w-9w Da.

[0057] In some embodiments of this application, when the composition comprises a combination of the above-mentioned hyaluronic acid or its salt, the above-mentioned collagenous substance and the above-mentioned chondroitin sulfate, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagenous substance to the mass of the hyaluronic acid or its salt is (0.5 to 200):1, the mass ratio of the chondroitin sulfate to the collagenous substance is (1 to 29):1, wherein the molecular weight of the collagenous substance is 1w-9w Da, and the molecular weight of the hyaluronic acid or its salt is 180w Da or less.

[0058] In some embodiments of this application, when the composition comprises a combination of the above-mentioned hyaluronic acid or its salt, the above-mentioned collagenous substance and the above-mentioned chondroitin sulfate, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagenous substance to the mass of the hyaluronic acid or its salt is (0.5 to 200):1, the mass ratio of the chondroitin sulfate to the collagenous substance is (1 to 29):1, wherein the molecular weight of the collagenous substance is 3w-7w Da, and the molecular weight of the hyaluronic acid or its salt is 180w Da or less.

[0059] For details regarding the aforementioned collagenous substances, the mass ratio of the aforementioned collagenous substances to the aforementioned hyaluronic acid or its salts, the mass ratio of the sum of the masses of the aforementioned chondroitin sulfate and the aforementioned collagenous substances to the mass of the aforementioned hyaluronic acid or its salts, and the mass ratio of hyaluronic acid or its salts, chondroitin sulfate, and the aforementioned collagenous substances, please refer to the above text, and it will not be repeated here.

[0060] This application provides the use of the above composition in cosmetics.

[0061] This application provides the use of the above composition in inhibiting and / or slowing down the decomposition of hyaluronic acid or its salts, and / or maintaining the action of hyaluronic acid or its salts.

[0062] This application provides a method for inhibiting and / or slowing down the decomposition of hyaluronic acid or its salts, and / or maintaining the effects of hyaluronic acid or its salts, the method comprising the following steps:

[0063] The above-mentioned collagenous substances, or a combination of the above-mentioned collagenous substances and the above-mentioned chondroitin sulfate, are added to an aqueous medium containing the above-mentioned hyaluronic acid or its salt.

[0064] In addition to water, the aqueous medium may also contain other ingredients suitable for use in cosmetics.

[0065] For details regarding the aforementioned collagenous substances, the mass ratio of the aforementioned collagenous substances to the aforementioned hyaluronic acid or its salts, the mass ratio of the sum of the masses of the aforementioned chondroitin sulfate and the aforementioned collagenous substances to the mass of the aforementioned hyaluronic acid or its salts, and the mass ratio of hyaluronic acid or its salts, chondroitin sulfate, and the aforementioned collagenous substances, please refer to the above text, and it will not be repeated here.

[0066] In this application, no restrictions are placed on the preparation method of the composition, which can be prepared in accordance with conventional methods in the art.

[0067] Example

[0068] Table 1. Materials and Equipment Information

[0069]

[0070] CS: Chondroitin sulfate; Col(A): Hydrolyzed product of collagen (A); Col(B): Hydrolyzed product of collagen (B); Col(C): Hydrolyzed product of collagen (C); Col(D): Hydrolyzed product of collagen (D); HA: Hyaluronic acid

[0071] Examples 1-14, Comparative Examples 1-9

[0072] Examples 1-14 and Comparative Examples 1-9 were prepared by mixing the components as described in Table 2, with the remainder being water, to obtain an aqueous solution of the mixture.

[0073] Experimental Example

[0074] Take a pre-prepared, sterilized petri dish and use a pipette to transfer 0.2 mL / cm³ of the mixture. 2 Add the liquid to the center and shake the watch glass to spread the liquid evenly on the surface (*Note: The liquid can level itself and does not require the use of a short glass rod).

[0075] After the surface is basically spread, place the surface dish in an oven to dry (37℃, RH20%, 30min) until basically dry;

[0076] Bacterial hyaluronidase was collected and prepared into an enzyme solution using an enzyme digestion medium (a buffer solution of disodium hydrogen phosphate-sodium dihydrogen phosphate-sodium chloride with 0.01% calcium chloride added, pH 6.5).

[0077] Using a pipette, 150 μL of enzyme solution was added to a basically dried petri dish containing the sample, spread evenly, and then the petri dish and the sample were placed in a transparent sealed bag.

[0078] Place the sample in a constant temperature oven (37℃) for a specified time (2h, 4h, 6h, etc.);

[0079] Once the allotted time has elapsed, the sample is removed and leached for collection.

[0080] The absorbance of the collected liquid was measured at 232 nm using a UV spectrophotometer.

[0081] When the detected absorbance is stable, the first time point when the absorbance reaches a stable value is regarded as the endpoint of HA degradation. At the same time, the corresponding control group without HA is used as a blank control. The absorbance at the time of complete degradation and the absorbance at the test time point are recorded.

[0082] The absorbance (At) at each time point / the absorbance (Ae) at the HA degradation endpoint is the HA degradation rate at each time point;

[0083] Note: The HA degradation rate detection method, enzyme solution preparation, and absorbance detection were carried out entirely in accordance with the description in Bloomage Biotechnology's published patent CN 109238995 A.

[0084] Parameter definition:

[0085] HA degradation rate = At / Ae × 100%

[0086] Where At is the absorbance value at each time point, and Ae is the absorbance value at the end of the enzymatic digestion.

[0087] The results of each embodiment and comparative example are shown in Table 2.

[0088] Table 2

[0089]

[0090]

[0091] Although the present invention has been disclosed above with reference to embodiments, it is not intended to limit the present invention. Anyone skilled in the art may make some modifications and refinements without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention shall be determined by the scope of the appended patent application.

Claims

1. Use of collagen-based substances, combinations of collagen-based substances and chondroitin sulfate, compositions containing collagen-based substances, or compositions containing collagen-based substances and chondroitin sulfate in the preparation of cosmetics that reduce the ability of hyaluronidase to degrade hyaluronic acid or its salts. The molecular weight of the collagen-like substance is 1w-9w Da; The hyaluronic acid or its salt has a molecular weight of less than 180 w Da; When the collagen-like substance or the composition containing the collagen-like substance is used to achieve the stated purpose, the mass ratio of the collagen-like substance to the hyaluronic acid or its salt is (0.5~200):1; or, When the combination of the collagen-like substance and chondroitin sulfate or the composition containing the collagen-like substance and chondroitin sulfate is used to achieve the intended use, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagen-like substance to the mass ratio of the hyaluronic acid or its salt is (0.5~200):1, and the mass ratio of the chondroitin sulfate and the collagen-like substance is greater than or equal to 1:

1.

2. The use according to claim 1, wherein, When the combination of the collagen-like substance and chondroitin sulfate is used to achieve the aforementioned purpose, the mass ratio of the chondroitin sulfate to the collagen-like substance is (1~29):

1.

3. Use of the composition in the preparation of cosmetics that reduce the ability of hyaluronidase to degrade hyaluronic acid; in, The composition includes hyaluronic acid or its salt, collagenous substances, and chondroitin sulfate; The molecular weight of the collagen-like substance is 1w-9w Da; The hyaluronic acid or its salt has a molecular weight of less than 180 w Da; The mass ratio of the sum of the masses of the chondroitin sulfate and the collagenous substance to the mass of the hyaluronic acid or its salt is (0.5~200):1; The mass ratio of chondroitin sulfate to the collagen-like substance is greater than or equal to 1:

1.

4. In the use according to claim 3, the mass ratio of chondroitin sulfate to the collagen-like substance is (1~29):

1.

5. A method for reducing the ability of hyaluronidase to degrade hyaluronic acid for non-therapeutic purposes, the method comprising the following steps: Add a collagen-like substance, or a combination of a collagen-like substance and chondroitin sulfate, or a composition containing a collagen-like substance, or a composition containing a collagen-like substance and chondroitin sulfate, to an aqueous medium containing hyaluronic acid or a salt thereof, wherein the collagen-like substance has a molecular weight of 1w-9w Da. The hyaluronic acid or its salt has a molecular weight of less than 180 w Da; When the collagen-like substance or the composition containing the collagen-like substance is used to implement the method, the mass ratio of the collagen-like substance to the hyaluronic acid or its salt is (0.5~200):1; or, When the combination of the collagen-like substance and chondroitin sulfate or the composition containing the collagen-like substance and chondroitin sulfate is used to implement the method, the mass ratio of the sum of the masses of the chondroitin sulfate and the collagen-like substance to the mass ratio of the hyaluronic acid or its salt is (0.5~200):1, and the mass ratio of the chondroitin sulfate and the collagen-like substance is greater than or equal to 1:

1.

6. The method according to claim 5, wherein the mass ratio of chondroitin sulfate to the collagen-like substance is (1~29):1.

Images